[Oncoinfo – Istantanee di Oncologia: seguici su [ Ссылка ]] How to select patients who are most likely to benefit from the chemotherapy? And how much immunotherapy do they really need? We talked about these and other open questions with Leisha A. Emens (President of Society for Immunotherapy of Cancer - SITC). She finally emphasized the importance of the recent FDA fully approved treatment for the triple negative breast cancer.
